Related Experiment Video
Updated: Apr 14, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
10.3K
Waldenström macroglobulinemia: What a hematologist needs to know
Prashant Kapoor1, Jonas Paludo2, Nishanth Vallumsetla3
1Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Blood Reviews
|April 18, 2015
Summary
Waldenström macroglobulinemia (WM) is a rare blood cancer. Recent discoveries in MYD88 and CXCR4 mutations are paving the way for targeted therapies to improve patient outcomes.
Area of Science:
- Hematologic Oncology
- Immunology
- Molecular Biology
Background:
- Waldenström macroglobulinemia (WM) is a lymphoplasmacytic bone marrow malignancy defined by IgM monoclonal protein.
- Patients are typically elderly, often asymptomatic at diagnosis, presenting with non-specific symptoms.
- Diagnostic clues include constitutional, neuropathy, and IgM-related hyperviscosity features.
Purpose of the Study:
- To review current management strategies for Waldenström macroglobulinemia.
- To highlight recent genetic discoveries (MYD88 and CXCR4 mutations) in WM.
- To discuss novel therapeutic targets and future treatment directions.
Main Methods:
- Literature review of recent advancements in WM diagnosis and treatment.
- Analysis of the impact of MYD88 and CXCR4 mutation discoveries on understanding WM pathogenesis.
- Synthesis of information on emerging therapeutic strategies.
Main Results:
- Identification of MYD88 and CXCR4 mutations has elucidated key signaling pathways in WM.
- These mutations offer potential targets for novel therapeutic interventions.
- Current management strategies are evolving with the integration of new therapies.
Conclusions:
- While WM remains incurable, novel therapies are improving its clinical course.
- Understanding genetic mutations provides a foundation for personalized treatment approaches.
- The future of WM management involves targeted therapies based on molecular profiling.
